Difference between revisions of "Template:Immunohistochemistry evaluation of invasive breast cancer"
Jump to navigation
Jump to search
(→Immunohistochemistry: +Global) |
m (→Immunohistochemistry: format) |
||
Line 4: | Line 4: | ||
For Ki-67 index, there are two main methods, a faster "hot spot" method and the more comprehensive ''IKWG global average'': | For Ki-67 index, there are two main methods, a faster "hot spot" method and the more comprehensive ''IKWG global average'': | ||
− | + | :Hot spot: | |
− | Hot spots are areas in which Ki-67 staining is particularly higher relative to the adjacent tumor areas.<ref name="ColemanJang2017">{{cite journal|last1=Coleman|first1=William B.|last2=Jang|first2=Min Hye|last3=Kim|first3=Hyun Jung|last4=Chung|first4=Yul Ri|last5=Lee|first5=Yangkyu|last6=Park|first6=So Yeon|title=A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method|journal=PLOS ONE|volume=12|issue=2|year=2017|pages=e0172031|issn=1932-6203|doi=10.1371/journal.pone.0172031}}</ref> | + | Hot spots are areas in which Ki-67 staining is particularly higher relative to the adjacent tumor areas.<ref name="ColemanJang2017">{{cite journal|last1=Coleman|first1=William B.|last2=Jang|first2=Min Hye|last3=Kim|first3=Hyun Jung|last4=Chung|first4=Yul Ri|last5=Lee|first5=Yangkyu|last6=Park|first6=So Yeon|title=A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method|journal=PLOS ONE|volume=12|issue=2|year=2017|pages=e0172031|issn=1932-6203|doi=10.1371/journal.pone.0172031}}</ref> Usually, the invasive edge of a tumor is a hot spot.<ref name="ColemanJang2017"/> When a tumor had several hot spots, the “hottest” spot is selected.<ref name="ColemanJang2017"/> Aim to count at least 500 cells in each case, but this is not always possible in cases with low tumor cell density and small tumor size.<ref name="ColemanJang2017"/> Also aim to include at least three high-power (×40 objective) fields.<ref name="DowsettNielsen2011">{{cite journal|last1=Dowsett|first1=M.|last2=Nielsen|first2=T. O.|last3=A'Hern|first3=R.|last4=Bartlett|first4=J.|last5=Coombes|first5=R. C.|last6=Cuzick|first6=J.|last7=Ellis|first7=M.|last8=Henry|first8=N. L.|last9=Hugh|first9=J. C.|last10=Lively|first10=T.|last11=McShane|first11=L.|last12=Paik|first12=S.|last13=Penault-Llorca|first13=F.|last14=Prudkin|first14=L.|last15=Regan|first15=M.|last16=Salter|first16=J.|last17=Sotiriou|first17=C.|last18=Smith|first18=I. E.|last19=Viale|first19=G.|last20=Zujewski|first20=J. A.|last21=Hayes|first21=D. F.|title=Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group|journal=JNCI Journal of the National Cancer Institute|volume=103|issue=22|year=2011|pages=1656–1664|issn=0027-8874|doi=10.1093/jnci/djr393}}</ref> |
− | |||
− | + | :IKWG global average:<ref name="NielsenLeung2021">{{cite journal|last1=Nielsen|first1=Torsten O|last2=Leung|first2=Samuel C. Y|last3=Rimm|first3=David L|last4=Dodson|first4=Andrew|last5=Acs|first5=Balazs|last6=Badve|first6=Sunil|last7=Denkert|first7=Carsten|last8=Ellis|first8=Matthew J|last9=Fineberg|first9=Susan|last10=Flowers|first10=Margaret|last11=Kreipe|first11=Hans H|last12=Laenkholm|first12=Anne-Vibeke|last13=Pan|first13=Hongchao|last14=Penault-Llorca|first14=Frédérique M|last15=Polley|first15=Mei-Yin|last16=Salgado|first16=Roberto|last17=Smith|first17=Ian E|last18=Sugie|first18=Tomoharu|last19=Bartlett|first19=John M. S|last20=McShane|first20=Lisa M|last21=Dowsett|first21=Mitch|last22=Hayes|first22=Daniel F|title=Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group|journal=JNCI: Journal of the National Cancer Institute|volume=113|issue=7|year=2021|pages=808–819|issn=0027-8874|doi=10.1093/jnci/djaa201}}</ref> | |
#Before first use, access the IKWG website (https://www.ki67inbreastcancerwg.org/) and complete the Ki67 calibration exercise | #Before first use, access the IKWG website (https://www.ki67inbreastcancerwg.org/) and complete the Ki67 calibration exercise | ||
#From Tools, link to the Online scoring app (or download and install the Ki67 counting app) and use the global method | #From Tools, link to the Online scoring app (or download and install the Ki67 counting app) and use the global method |
Revision as of 11:09, 23 July 2021
Contents
Immunohistochemistry
Ki-67 index
For Ki-67 index, there are two main methods, a faster "hot spot" method and the more comprehensive IKWG global average:
- Hot spot:
Hot spots are areas in which Ki-67 staining is particularly higher relative to the adjacent tumor areas.[1] Usually, the invasive edge of a tumor is a hot spot.[1] When a tumor had several hot spots, the “hottest” spot is selected.[1] Aim to count at least 500 cells in each case, but this is not always possible in cases with low tumor cell density and small tumor size.[1] Also aim to include at least three high-power (×40 objective) fields.[2]
- IKWG global average:[3]
- Before first use, access the IKWG website (https://www.ki67inbreastcancerwg.org/) and complete the Ki67 calibration exercise
- From Tools, link to the Online scoring app (or download and install the Ki67 counting app) and use the global method
- Using a regular light microscope, review the Ki67-stained breast cancer slide and input estimates of the percent area with negligible, low, medium, or high Ki67 index
- Score 100 nuclei negative or positive in each field type (as directed by the app)
- Record “Weighted global score” output as the Ki67 index for that slide
Regardless of method:[2]
- If a comparisons must be made between core biopsies and sections from an excision, evaluation of the latter should be across the whole tumor.
- Only nuclear staining counts. Staining intensity of a positive nucleus is not relevant.
HER2/neu
Score[4] | Status[4] |
---|---|
0 to 1+ | HER2 negative (not present) |
2+ | Borderline |
3+ | HER2 positive |
Notes
Main page
References
- ↑ 1.0 1.1 1.2 1.3 Coleman, William B.; Jang, Min Hye; Kim, Hyun Jung; Chung, Yul Ri; Lee, Yangkyu; Park, So Yeon (2017). "A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method ". PLOS ONE 12 (2): e0172031. doi: . ISSN 1932-6203.
- ↑ 2.0 2.1 Dowsett, M.; Nielsen, T. O.; A'Hern, R.; Bartlett, J.; Coombes, R. C.; Cuzick, J.; Ellis, M.; Henry, N. L.; et al. (2011). "Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group ". JNCI Journal of the National Cancer Institute 103 (22): 1656–1664. doi: . ISSN 0027-8874.
- ↑ Nielsen, Torsten O; Leung, Samuel C. Y; Rimm, David L; Dodson, Andrew; Acs, Balazs; Badve, Sunil; Denkert, Carsten; Ellis, Matthew J; et al. (2021). "Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group ". JNCI: Journal of the National Cancer Institute 113 (7): 808–819. doi: . ISSN 0027-8874.
- ↑ 4.0 4.1 . IHC Tests (ImmunoHistoChemistry). Breastcancer.org. Retrieved on 2019-10-04. Last modified on October 23, 2015
Image sources